000			02061 a2200601 4500
005			20250518082642.0
264		0	_c20200317
008			202003s 0 0 eng d
022			_a1432-0584
024	7		_a10.1007/s00277-020-03932-8 _2doi
040			_aNLM _beng _cNLM
100	1		_aMartín, Iván
245	0	0	_aImpact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. _h[electronic resource]
260			_bAnnals of hematology _cMar 2020
300			_a527-537 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAzacitidine _xadministration & dosage
650	0	4	_aChromosome Deletion
650	0	4	_aChromosomes, Human, Pair 7 _xgenetics
650	0	4	_aCyclin-Dependent Kinase Inhibitor p15 _xgenetics
650	0	4	_aDNA Methylation _xdrug effects
650	0	4	_aDNA, Neoplasm _xgenetics
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aGTPase-Activating Proteins _xgenetics
650	0	4	_aHumans
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyelodysplastic Syndromes _xdrug therapy
650	0	4	_aNucleophosmin
650	0	4	_aPromoter Regions, Genetic
650	0	4	_aSurvival Rate
650	0	4	_aTumor Suppressor Proteins _xgenetics
700	1		_aNavarro, Blanca
700	1		_aSerrano, Alicia
700	1		_aVillamón, Eva
700	1		_aCalabuig, Marisa
700	1		_aSolano, Carlos
700	1		_aChaves, Felipe Javier
700	1		_aYagüe, Nuria
700	1		_aOrts, Maribel
700	1		_aAmat, Paula
700	1		_aFuentes, Azahara
700	1		_aSeda, Enrique
700	1		_aGarcía, Francisca
700	1		_aHernández-Boluda, Juan Carlos
700	1		_aTormo, Mar
773	0		_tAnnals of hematology _gvol. 99 _gno. 3 _gp. 527-537
856	4	0	_uhttps://doi.org/10.1007/s00277-020-03932-8 _zAvailable from publisher's website
999			_c30567761 _d30567761